Stock VYNE VYNE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : VYNE Therapeutics Inc.

Analyst Reco. VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq
Other stock markets
 04:00:00 2023-12-01 pm EST 		Intraday chart for VYNE Therapeutics Inc. 5-day change 1st Jan Change
3.470 USD +4.83% -13.47% +28.52%
Nov. 13 Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000 MT
Nov. 13 VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Analyst Reco.

Search
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating
MT
HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating
MT
HC Wainwright Cuts VYNE Therapeutics' Price Target to $1.50 From $7, Maintains Buy Rating
MT
HC Wainwright Assumes VYNE Therapeutics at Buy with $7 Price Target
MT
VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keeps Outperform Rating
MT
VYNE THERAPEUTICS : HC Wainwright Adjusts VYNE Therapeutics' Price Target to $11 from $14, Keeps Buy Rating
MT
VYNE THERAPEUTICS : Barclays Adjusts Price Target for VYNE Therapeutics to $15 From $12, Maintains Overweight Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Filters

Announcement Date

Since

Until

  1. Stock
  2. Equities
  3. Stock VYNE Therapeutics Inc. - Nasdaq
  4. News VYNE Therapeutics Inc.
  5. Analyst Reco.
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits
fermer